growth hormone, follicle stimulating hormone and thyrotropin from the pituitary gland (Krulich et al., 1968; Brazeau et al., 1973; Hall et al., 1978; Reichlin, 1983) and several peptide hormones from the endocrine gut and pancreas (Cohen et al., 1978; Gerich, 1981) . It also affects exocrine and other functions of the gut, i.e. inhibits motility and absorption and decreases gut blood flow (cf. Arnold & Lankisch, 1980) . Somatostatin also inhibits flushing in the carcinoid syndrome by reducing peripheral serotonin (5-HT) levels (Frolich et al., 1978) .
Recently synthetic somatostatin analogues have become available. Such compounds have been used both chronically and acutely to relieve symptoms caused by excessive secretion of tumour products (biogenic amines, peptide hormones) from carcinoid lesions of the gastrointestinal tract (cf. Bloom & Greenwood, 1985; Kvols et al., 1985) . Such analogues may act at several levels, i.e. impaired release of tumour products, interaction with released peptides, blockade or desensitation of tumour receptors.
With clinical experience of one somatostatin analogue in the chronic management of patients with carcinoid tumours (Ahlman & Tisell, 1987) matic reaction, but biochemically slowly increasing levels of 5-HT were demonstrated (Table I ). To avoid adverse reactions of 5-HT at surgery/anaesthesia she was also treated with peripheral blockade of 5-HT2-receptors using ketanserin (Janssen Pharmaceuticals, Beerse, Belgium) (cf. Ahlman et al., 1985) . During surgery (ileocecal resection with microdissection of metastatic lymph nodes around the superior mesenteric artery, left sided salpingo-oophorectomy, prophylactic cholecystectomy and surgical division of collaterals in the hepatic ligaments prior to future embolisation therapy) and on the first post-operative day she was given a total dose of SMS 201-995 of 400,ug daily (100 ugx4s.c.) in addition to ketanserin (20mgx2i.v.). Surgery was uneventful. During convalescence this patient injected herself daily with SMS 201-995 50.ugx2s.c. Four weeks later she had almost normal basal levels of 5-HT, while urinary 5-HIAA was still elevated (589jmol 24h-1; ref. 0-50). She was essentially symptom-free when she returned for embolisation of the right hepatic artery. Broad spectrum antibiotics were given preoperatively (cf. Maton et al., 1983) . Embolisation was monitored by fluoroscopy and the procedure was terminated when injected contrast medium stayed in main arterial branches for more than 30sec (Lunderquist et al., 1982) . Identical treatment with SMS 201-995 and ketanserin was given in conjunction with this procedure as during previous surgery. Slight flush, but no blood pressure reaction, was seen at embolisation. Since the arterial blood pressure remained stable, an epidural anaesthetic with marcaine (4%) was applied for analgesia. During the following 6 week period the patient was continuously treated with SMS 201-995 (50jgx2s.c.). She developed slight steatorrhea probably due to suppression of pancreatic exocrine secretion by the somatostatin analogue, which was effectively treated with substitution of pancreatic enzymes. Before the left hepatic artery was embolised, this patient underwent a second PG-test, which demonstrated normal basal levels of 5-HT and no release reaction (Table I) . She had identical perioperative treatment with SMS 201-995 and ketanserin at the second embolisation, which was also uneventful. One week after completion of the surgical and embolisation treatment SMS 201-995 was withdrawn to evaluate the therapeutic effects. The patient remained symptomfree and had normal 5-HT levels before and after provocation with PG, while 5-HIAA levels were still elevated (Table I) .
A cell suspension with high viability (91%) was prepared from this tumour to investigate the type of adrenoceptors involved in the release of 5-HT (cf. Nilsson et al., 1986) . One suspension of tumour cells (12 x 106cells ml -1) was incubated in Kreb's solution with various concentrations of adrenoceptor agonists added. Compared with controls in Kreb's solution alone, noradrenaline elicited a pronounced dose-dependent release of 5-HT to the medium, which increased with incubation time (Figure la) . Isoprenaline caused a much less pronounced release of 5-HT with a slower time course than NA ( Figure Ib) . A diluted suspension of tumour cells (3 x 106cells ml-1) was studied for 15 min after incubation with a calcium ionophore (A23187 10-5 M), which caused a 5-HT release which progressively increased with time of incubation (Figure 2) . Thus, the clinical use of calcium and adrenergic drugs should be strictly avoided; in this patient such combined treatment may well have been deleterious.
In the present case of the midgut carcinoid syndrome pretreatment with SMS 201-995 resulted in decreased levels of one tumour marker (5-HT in peripheral whole blood) associated with the disappearance of specific symptoms. Table I 5-HT levels in peripheral whole blood and 5-HIAA levels in urine of a patient with the carcinoid syndrome during treatment with a somatostatin analogue. When the basal levels of 5-HT were significantly depressed after 6 days of pretreatment, the patient underwent a provocation test with PG without subjective discomfort despite objective release of 5-HT at injection with PG (Table   I ). The biochemical outcome of this test suggested blockade of peripheral 5-HT receptors by SMS 201-995 rather than an inhibited release of 5-HT. It must be emphasized, however, that there may be several other tumour products synthesized by midgut carcinoids besides 5-HT, e.g. peptide hormones of the tachykinin family, which also are released by PG (Norheim et al., 1986 (Table I) effects additional to those seen at acute administration of the drug.
In conclusion, new synthetic somatostatin analogues may prove to be important tools to protect patients with advanced endocrine malignancies against life-threatening reactions caused by excessive release of tumour-produced amines and peptides during surgery or hepatic arterial embolisation. In order to evaluate the efficacy of such prophylactic treatment, provocation tests with monitoring of tumour markers may be very useful to obtain an adequate dosage of the drug. This study was supported by the Swedish MRC (5220, 2207) and the MRC of the Swedish Health Insurance Companies.
